General Proximity Announces A Strategic Multi-Target Collaboration with Daiichi Sankyo

General Proximity has announced a strategic collaboration with Daiichi Sankyo to utilize its OmniTAC discovery platform for oncology programs. This partnership aims to develop induced proximity medicines that target disease-driving proteins, creating therapeutic opportunities for previously undruggable targets. The collaboration will focus on discovering novel effector-target pairs for potential first-in-class therapies, while also expanding OmniTAC's application in cardiometabolic disease, neurodegeneration, and longevity.